Of 234 drug trials that had become due to report results, only 116 had reported results on time. A further 20 trials reported results late, and 98 trials completely failed to make substantive results public.

According to an internal analysis, 29.6% of studies that are highly likely to fall under mandatory reporting requirements have no results information submitted to ClinicalTrials.gov.

FAST EU is directed to Facilitating and accelerating strategic clinical trials in the EU

Spain, France, Germany, Italy and Poland have access to the largest numbers of drug trials.

Ten Guiding Principles of Good AI Practice in Drug Development is mentioned in the guidance